A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver
This study has been completed.
Study NCT00001587
Information provided by National Institutes of Health Clinical Center (CC)
First Received: November 3, 1999
Last Updated: March 3, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
